FDA Approves Dexcom G6 Pro CGM for Use in Diabetes FDA Approves Dexcom G6 Pro CGM for Use in Diabetes

Dexcom G6 Pro is a single-use, professional CGM that gathers real-time glucose data over 10 days and offers both a blinded and unblinded mode, enabling choice of whether patient sees the data or not.FDA Approvals
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Diabetes & Endocrinology News Alert Source Type: news

Related Links:

ConclusionT1D prevalence is constantly increasing worldwide, but at slower pace in Africa in comparison to developed countries. Difficulties to access to high standard care and population poverty in Sub-Saharan Africa, represents a major independent factor of poor therapeutic observance.
Source: International Journal of Pediatrics and Adolescent Medicine - Category: Pediatrics Source Type: research
In conclusion, Chinese postmenopausal women with T2DM had a similar risk of incident VFs, but a significantly higher risk of incident non-VF, compared to women without DM. Higher BMI did not modify the effect of T2DM on risk of VFs, but it increased the association be tween T2DM and risk of non-VFs. LS BMDT-score was similarly and negatively associated with VF risk in T2DM and non-DM women and appear to be useful for clinical evaluation of VF risk.
Source: Calcified Tissue International - Category: Orthopaedics Source Type: research
ConclusionThe technical considerations for performing a LeFort Colpocleisis include ruling out malignancy prior to surgery, adequate lateral channels for uterine drainage, the use of lidocaine with epinephrine, closure in multiple layers with excellent hemostasis and an aggressive posterior colpoperineorrhaphy.
Source: Journal of Minimally Invasive Gynecology - Category: OBGYN Source Type: research
Source: Critical Reviews in Food Science and Nutrition - Category: Nutrition Authors: Source Type: research
They found that patients with diabetic macular edema had a much higher rate (80.6%) of severe sleep apnea than those without the eye condition (45.5%).
Source: WebMD Health - Category: Consumer Health News Source Type: news
Authors: Avinash M, Renjith KR, Shetty AP, Sharma V, Kanna RM, Rajasekaran S Abstract Study design: Prospective study. Purpose: Last decade has witnessed the emergence of unplanned readmissions as a tool to gauge health-care quality and hospital performance. Previous studies were limited by their retrospective designs based on data-base information and short-term 30-day follow-up intervals. We analyzed incidence and causes for unplanned readmissions following spine surgery at 90-d interval and its difference at 30-d, 31-60-d and 61-90-d intervals, Total Bed-Days Lost (TBL) and economic impact of readmissions an...
Source: Asian Spine Journal - Category: Orthopaedics Tags: Asian Spine J Source Type: research
The reach of Senseonics Holdings’ continuous glucose monitoring system became a bit longer. The Germantown, MD-based company announced that Health Care Service Corporation (HCSC) - Blue Cross Blue Shield is now providing coverage for the Eversense CGM System. This recent coverage decision adds to the growing number of payers who are writing Eversense into their CGM coverage policies, as well as paying for the healthcare provider’s time for the in-office sensor placement. “Having HCSC recognize Eversense as one of their covered diabetes management tools demonstrates that...
Source: MDDI - Category: Medical Devices Authors: Tags: Regulatory and Compliance Source Type: news
Publication date: Available online 14 October 2019Source: The Lancet Diabetes &EndocrinologyAuthor(s): Dinesh Selvarajah, Debasish Kar, Kamlesh Khunti, Melanie J Davies, Adrian R Scott, Jeremy Walker, Solomon TesfayeSummaryDiabetic peripheral neuropathy (DPN) is a common complication of both type 1 and 2 diabetes. It is a leading cause of lower-limb amputation and disabling neuropathic pain. Amputations in patients with diabetes have a devastating effect on quality of life and are associated with an alarmingly low life expectancy (on average only 2 years from the amputation). Amputation also places a substantial financ...
Source: The Lancet Diabetes and Endocrinology - Category: Endocrinology Source Type: research
Publication date: Available online 14 October 2019Source: The Lancet Diabetes &EndocrinologyAuthor(s): Athanasios Fountas, Stan Van Uum, Niki KaravitakiSummaryThe use of opioids is becoming a global epidemic, leading to a rise in the occurrence and recognition of the effects of opioid drugs on the endocrine system. Nonetheless, opioid-induced endocrinopathies still remain underdiagnosed, mainly because of symptom under-reporting by patients and poor clinician awareness. Hypogonadism is the most well recognised consequence of opioid use, but the inhibitory effects of opioid drugs on the hypothalamo–pituitary&ndash...
Source: The Lancet Diabetes and Endocrinology - Category: Endocrinology Source Type: research
DiabetesMine continues its series of interviews with the 2019 Patient Voices Contest winners.
Source: Diabetes Mine - Category: Endocrinology Authors: Source Type: blogs
More News: Diabetes | Endocrinology | Health